Pre-made Tisotumab benchmark antibody ( Whole mAb, anti-F3 therapeutic antibody, Anti-CD142/TF/TFA Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tisotumab biosimilar, Whole mAb, Anti-F3 Antibody: Anti-CD142/TF/TFA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tisotumab vedotin, also known as HuMax-TF, HuMax?-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate or ADC targeted to Tissue Factor (TF), a protein involved in tumor signaling and angiogenesis.
| Products Name (INN Index) | Pre-Made Tisotumab biosimilar, Whole mAb, Anti-F3 Antibody: Anti-CD142/TF/TFA therapeutic antibody |
|---|---|
| INN Name | Tisotumab |
| Target | F3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Genmab,Seattle Genetics |
| Conditions Approved | NA |
| Conditions Active | Bladder cancer,Cervical cancer,Endometrial cancer,Fallopian tube cancer,Oesophageal cancer,Ovarian cancer,Peritoneal cancer,Prostate cancer,Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | F3 |
| Package |
